Introduction
Randomized, controlled clinical trials are the gold standard of evidence for assessing the efficacy and safety of new drugs and medical devices. Randomization is a fundamental element of clinical trial quality that ensures comparable groups and avoids bias, while the controlled environment of these trials is critical for comparing interventions to placebo or other standards of care. While many trials lead to approval of new medications or optimization of existing therapies, clinical trials are taking longer, are increasingly complex, and cost more than ever before. Some have questioned whether current clinical trials are even being designed to answer the most relevant questions posed by patients, practicing physicians, and our health care system. 1 At a time when the United States health care system is in need of highquality data on topics ranging from antimicrobial resistance to cost containment strategies, it is essential to improve the quality and efficiency of our clinical trials enterprise to deliver the consistent, efficient, high-quality evidence necessary to drive medicine forward.
The CTTI mission
Ten years ago, to address the challenges facing clinical trials, the U.S. Food and Drug Administration (FDA) and Duke University established a public-private partnership, the Clinical Trials Transformation Initiative (CTTI). CTTI's mission is ''To develop and drive adoption of practices that increase the quality and efficiency of clinical trials.'' To this end, CTTI brings together diverse stakeholders to identify and address barriers to the conduct of efficient and meaningful clinical trials. This supplement reflects on 10 years of CTTI's efforts to transform the clinical trials enterprise and the challenges still ahead.
CTTI organization and membership
Administratively, CTTI is a partnership between the FDA and Duke University. In practice, however, CTTI is a broadly engaged and widely influential organization. An Executive Committee provides strategic direction and oversight while CTTI staff, led by an executive director, provides operational structure. However, it is CTTI's broad multi-stakeholder membership, including representatives from across the clinical trials enterprise, which is CTTI's defining characteristic. CTTI has more than 80 member organizations, including government agencies, academic organizations and investigator groups, biopharmaceutical and medical device developers, contract research organization (CRO), professional societies, and patient advocacy groups. Together, these member organizations identify and prioritize projects and comprise the project teams that identify best practices, then develop and disseminate evidence-based solutions to critical issues facing the clinical trials enterprise. Through this membership and organizational structure, CTTI provides a venue for open, multi-stakeholder discussion on issues that impact the quality and efficiency of medical research across the clinical trials enterprise.
FDA engagement and inter-organizational alignment
Fundamental to CTTI's impact is the FDA's support and engagement. FDA personnel are engaged in roles ranging from executive leadership to participation on project teams. Involvement on a variety of levels enables the FDA to gain a broad multi-stakeholder perspective on issues relevant to the conduct of clinical trials by participating in open, transparent dialogue. This dialogue benefits the FDA and other stakeholders alike.
To 
Patient voice
Another of CTTI's defining features is the emphasis placed on the patient voice. Many years ago, CTTI recognized the value of the patient perspective in promoting efficient trial conduct and improving the availability of treatment options. Together, individual patients, their caregivers, and advocacy organizations represent an important group that contributes to the development of initiatives in support of CTTI's mission. CTTI has promoted patient engagement through the development of specific projects on best practices, and by advocating for and integrating the patient voice in project creation and execution.
CTTI: present and future
The unique nature of the collaboration fostered by CTTI's structure and membership has contributed to improved efficiency and quality of clinical trials. Many are explored in this supplement in greater detail. Corneli et al. describe the methodology that provides the foundation for CTTI's work; Tenaerts, Madre, and Landray explore the common themes and lessons learned that have emerged from the recommendations and tools CTTI has produced to date; Corneli et al. describe the methodology that provides the foundation for CTTI's work; Glessner and Meeker-O'Connell describe the evolution of quality approaches to clinical trials and CTTI's role in driving quality-by-design; Patrick-Lake takes a closer look at CTTI's patient engagement activities in clinical trials; and Eichler and Sweeney explore challenges for the future of clinical trials.
Much work still remains after CTTI's first decade; while the challenges are great, new opportunities for improvement of the clinical trials enterprise continue to emerge. For example, the proliferation of electronic data, including medical records and patient-generated data, holds the promise of developing ''real world'' evidence to support treatment approaches outside the tightly controlled environment of a traditional randomized controlled clinical trial. Real-world evidence is especially promising if randomized trials can be adapted to include much broader populations by leveraging these data sources. Furthermore, innovative statistical methods, novel ways of identifying and enrolling patients in trials, and new methods supporting very broad-based trials can make research more efficient and lower the costs of developing high-quality evidence to support medical decision making. CTTI's work will focus on each of these areas going forward.
Recently, CTTI has shifted its focus toward driving the adoption of CTTI recommendations and measuring their impact on the clinical trials enterprise. Achieving meaningful change requires more than ''best practice'' recommendations, even if these are evidence-based and developed with broad support. To this end, CTTI is now redirecting prior recommendations toward groups or individuals most likely to be drivers of change. Identifying actionable recommendations and targeting these recommendations toward the levers of change is the key to CTTI's future success. In the coming years, CTTI's vision will continue to guide the evolution of the clinical trials enterprise toward a high-quality, global system that is patient-centered and efficient, thereby enabling reliable and timely access to evidence-based therapeutic prevention and treatment options. We look forward to your participation in achieving this vision.
